arrow
E

Emily Capone

university of chieti-pescara g. d'annunzio
H指数:19
被引数:1,057

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

糖基化的LGALS3BP由膀胱癌细胞高度分泌,并代表了一种新型的尿液疾病生物标志物。

2025-10-050
OAAI
A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy

一种基于重组人铁蛋白的新型非细胞毒性纳米载体,可增强靶向治疗、化疗和免疫治疗。

2025-05-010
PRE
LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth

LGALS3BP抗体药物偶联物增强肿瘤浸润淋巴细胞,并与免疫疗法协同作用以抑制神经母细胞瘤生长

2025-04-110
OA
Vesicular LGALS3BP is a neuroblastoma biomarker and a therapeutic target for combination therapy with antibody-drug conjugate and checkpoint inhibitors

囊泡LGALS3BP是一种神经母细胞瘤生物标志物,也是抗体-药物偶联物和检查点抑制剂联合治疗的治疗靶点

2024-03-220
PRE
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma

Anti-LGALS3BP抗体-药物缀合物治疗在腺样囊性癌的临床前模型中诱导持久且有效的抗肿瘤反应

2024-01-017
OAAI
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma

细胞外LGALS3BP: 胶质母细胞瘤中抗体药物缀合物治疗的潜在疾病标志物和可操作靶标

2023-06-0717
OAAI
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
2022-03-2813
OAAI